Pharmaceutical Products / Drugs Technology Offers

Technology Categories

By Type

LUCIA CORAL posted this:
Knowledge Tranfer Manager at National Cancer Institute CRO Aviano

Cell models to evaluate activity of p53:MDM2 inhibitors Twist GAIN-of-function and LOSS-of-function cell models were developed and used for preclinical p53:MDM2 inhibitors evaluation, preliminary demonstrating that the expression of Twist hampers their efficacy. These findings support patient stratification on the basis of twist expression for treatment of a large fraction of sarcomas but also of a fraction of carcinomas. (Piccinin et al., Cancer Cell, 22, 404-415, Sept 11 2012).

Cell models to evaluate activity of p53:MDM2 inhibitors

Udit Mangal posted this:
Vice President- Business Development at Pluss Advanced Technologies Pvt. Ltd.

Phase Change Material Based Temperature Control Solutions for biological samples, test kits and vaccines At Pluss, we bear distinction of doing innovative and sustainable solutions in the field of temperature control using our core Phase Change Material (PCM) technology. One of our lead products is Celsure®, a set of pre-qualified shipping boxes for maintaining the temperature of your vaccines or other heat labile products for up to 120 hours between 2-8 deg C, 15-25 deg C and frozen (-20 deg C) as the case may be, with a variety of payload volumes (https://www.pluss.co.in/celsure/). Besides the prolonged back up hours, the unique design of the solution allows for complete freeze prevention way of storing vaccines in case of 2-8 temperature maintenance.

OTRI-Universidad de Málaga posted this:
Technology Transfer Office (TTO) at Universidad de Málaga

NEUROPEPTIDE IN THE PREVENTION AND / OR TREATMENT OF DISORDERS AND ALCOHOL-RELATED EFFECTS The present invention relates to the use of galanin(1-15), or an analogue thereof, for use in the prevention and/or treatment of alcohol-related effects and disorders, especially the use thereof to reduce alcohol consumption.

Dr. Thomas Kallimopoulos posted this:
CEO at Extranthis UG

Drug Development of a Natural Product for Non-addictive Opioid Use Disorder Treatment Drug development of a natural product which presents a strong potential to treat addiction to opioids without developing addictive side effects to patients.

Drug Development of a Natural Product for Non-addictive Opioid Use Disorder Treatment

Dr. Thomas Kallimopoulos posted this:
CEO at Extranthis UG

Cytisine - Smoking cessation agent - We provide supply of cGMP cytisine API in bulk, produced in FDA inspected installations in the USA, for use as smoking cessation agent. - We develop a small molecule (natural product) for treatment of opioids use disorder and for pain management.

Cytisine - Smoking cessation agent

OTRI-Universidad de Málaga posted this:
Technology Transfer Office (TTO) at Universidad de Málaga

NEW THERAPEUTIC TARGET IN THE TREATMENT OF ALZHEIMER A study carried out through the use of systems biology, with the analysis of complex data, starting with omics data and using integrative tools for the analysis of dynamic and modular responses, has identified a candidate target and the use of its inhibitor as new useful drug to combat Alzheimer's disease. The present invention refers to the total or partial inhibition of the expression of the localized gene, or of the activity of the enzyme encoded by said gene, to be used for the treatment of Alzheimer's disease.

NEW THERAPEUTIC TARGET IN THE TREATMENT OF ALZHEIMER

UNIVERSIDAD DE BURGOS posted this:

Photocatalyzers of ruthenium (II) and photocatalytic synthesis of iminas.Ruthenium (II) photocatalysts of formula (M +) nXn- are described, in which Xn- is an anion and M + is a cationic complex of formula (Ia) comprising an 8-arylsulfonamidoquinoline ligand, as well as its method of obtaining it. The use of said ruthenium (II) photocatalysts in the synthesis of imines by photooxidation of amines in the presence of oxygen and by the use of visible light is also described.

Arkadiusz Rudawski, PhD posted this:
Technology Broker at Cracow University of Technology

A modern form of formulation on burn wound healing, containing bioactive lavender oil (Lavandula angustifolia)The subject of the invention will be a nanoformulation containing as a therapeutic ingredient bioactive lavender oil (Lavandula angustifolia).

Alireza Daneshvar posted this:
Pharmacy Student and Researcher at Tehran University of Medical Sciences

COVID-19 Rapid Diagnostic Kit Designing and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test for COVID-19 assessment. One of the most important problems of this diagnostic test is the time needed by the device to detect infected persons. This problem makes big companies in the field of pharmaceutical and medical devices manufacturing to design and develop rapid test kits. Our research team found that there are some specific proteins on the viral membrane which can make some reagents undergo a specific chemical reaction. Every reaction has a specific product related to substrates, so by detection of products with indicator reagents we are able to identify the virus in saliva. Indicator reagents usually change the reaction mixture color so by color change we can approve that the person is infected by COVID-19. The advantages of using saliva include: specimen collection can be done without a healthcare professional no additional equipment such as swabs or transport media are needed as nasopharyngeal specimens can be 'uncomfortable' use of saliva-based testing may encourage recruits to clinical trials of vaccines. So far two prototypes have been designed: 1) For Home Testing: Disposable test kits where an individual adds a saliva sample into a vial containing the indicator reagent, the presence of the COVID-19 virus is indicated by a positive test as shown by a colour change. 2) Reusable Low Cost Test Kits for Healthcare Professionals: Where there is a low concentration of virus in saliva, for example in the first days after infection, viral proteins can be concentrated using a saliva condensation function. In this situation, multiple samples of saliva are placed into a device which can condensate the samples to increase concentration of any virus present. After the test has been completed, the vessel can be disinfected for ready for re-use. One of the most important properties of this approach is a much lower error rate than has been found in other devices. (errors found in other tests are in various submitted articles to different journals). The re-usable nature of this professional test could make it a practical solution for low-income countries where large scale expensive PCR testing is not an option.

COVID-19 Rapid Diagnostic Kit

Covid-19 Innovation Challenges by Innoget posted this:

Expertise in molecular biology either experimentally or computationally The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally

IBB-UAB posted this:

Expertise in molecular biology either experimentally or computationally The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally

TEC Edmonton posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Covid-19 Innovation Challenges by Innoget posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Pascal Mayer posted this:
CEO at Alphanosos

Alphanosos rapid discovery technology against COVID 19 Alphanosos’ AI guided rapid discovery technology, validated in antimicrobials and anticancer, is expected to develop within 3 weeks of experimental work with a virology partner an anti-COVID-19 treatment composed of a synergistic mix of extracts of edible plants, chosen for being available in large amounts and with good traceability. Such treatment is, therefore, and also thanks to the innovative elaboration process, immediately available to enter large curative clinical trials, to be followed by country-wide deployment in a matter of weeks, for curative and for preventive goals (because of safety which is guaranteed by the edible nature of the mix).

Alphanosos rapid discovery technology against COVID 19

Universitat Politècnica de Catalunya - UPC posted this:

Fast cardiovascular condition assessment An easy-to-use and affordable system able to determine several cardiovascular parameters from unsupervised measurements easily obtained at hands or feet.

Fast cardiovascular condition assessment

1
2
3
4
5